Deakin University
Browse

File(s) under permanent embargo

Monitoring the safe use of Clozapine : a consensus view from Victoria, Australia

journal contribution
posted on 2007-01-01, 00:00 authored by Michael BerkMichael Berk, J Fitzsimons, T Lambert, C Pantelis, J Kulkarni, D Castle, E Ryan, S Jespersen, P McGorry, G Berger, B Kuluris, Thomas Callaly, Seetal DoddSeetal Dodd
Clozapine is an important antipsychotic agent that has a unique profile of clinical benefits, but that has also been associated with several serious and potentially life-threatening safety concerns. In order to minimise the impact of haematological adverse events, health professionals treating patients with clozapine are currently required to register their patients on a centrally administered data network and to conform to strict protocols. The consensus statement documented in this article extends existing protocols by recommending monitoring of patients treated with clozapine for additional adverse effects during treatment. This consensus statement reflects the current practice at five major public psychiatric hospitals in Victoria, Australia, for the monitoring and management of clozapine-related adverse events, and has been implemented at these sites because of emerging safety concerns associating clozapine with cardiovascular and metabolic adverse effects.

History

Journal

CNS drugs

Volume

21

Issue

2

Pagination

117 - 127

Publisher

ADIS International

Location

London, England

ISSN

1172-7047

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

2007, ADIS International